New Lifetime High For Bluebird Bio (BLUE)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified bluebird bio ( BLUE) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified bluebird bio as such a stock due to the following factors:

  • BLUE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $199.5 million.
  • BLUE has traded 11,421 shares today.
  • BLUE is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BLUE with the Ticky from Trade-Ideas. See the FREE profile for BLUE NOW at Trade-Ideas

More details on BLUE:

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Currently there are 9 analysts that rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for bluebird bio has been 762,700 shares per day over the past 30 days. Bluebird bio has a market cap of $5.9 billion and is part of the health care sector and drugs industry. Shares are up 100.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates bluebird bio as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.

Highlights from the ratings report include:

  • BLUEBIRD BIO INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, BLUEBIRD BIO INC reported poor results of -$1.78 versus -$0.80 in the prior year. For the next year, the market is expecting a contraction of 78.1% in earnings (-$3.17 versus -$1.78).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 133.6% when compared to the same quarter one year ago, falling from -$10.61 million to -$24.79 million.
  • Net operating cash flow has significantly decreased to -$24.16 million or 102.43% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, BLUEBIRD BIO INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Compared to its closing price of one year ago, BLUE's share price has jumped by 643.82%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in BLUE do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017